New Standard of Care for Previously Untreated CLL

Professor Peter Hillmen from the University of Leeds discussed the results of the FLAIR trial at ASH 2023. The phase III trial focused on treating CLL with a combination of ibrutinib+venetoclax compared to FCR. The study’s primary endpoint was progression-free survival, showing a significant advantage for the ibrutinib+venetoclax combination. Overall survival also favored this combination, with notable benefits across various disease subgroups. The data support this combination as a New Standard of Care for Previously Untreated CLL.